Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate |
2011-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2020-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-102061353-B1 |
titleOfInvention |
Inhibitors of human ezh2, and methods of use thereof |
abstract |
The present invention relates to the inhibition of wild type and certain mutant forms of human histone methyltransferase EZH2, which is a catalytic subunit of the PRC2 complex that promotes monomethylation to trimethylation of lysine 27 (H3-K27) on histone H3. In one embodiment, the inhibition is selective for the mutant type of EZH2 such that trimethylation of H3-K27 associated with certain cancers is inhibited. The method can be used to treat cancer, including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying selective small molecule inhibitors of mutant forms of EZH2 and also for determining reactivity to EZH2 inhibitors in a subject. |
priorityDate |
2010-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |